Connect
← Return to Oral teriparatide tablet (EB613) gets FDA nod for Phase 3 trial
Discussion
Oral teriparatide tablet (EB613) gets FDA nod for Phase 3 trial
Osteoporosis & Bone Health | Last Active: Jun 30 2:13pm | Replies (28)Comment receiving replies
@mayblin Very exciting development!
I read: Phase 3 initiation is planned for late 2026 with topline data anticipated in the second half of 2028.
Do you know how to interpret that statement in terms of when this might be available to the general public?
Replies to "@mayblin Very exciting development! I read: Phase 3 initiation is planned for late 2026 with topline..."
Connect
@tillymack i feel the same way.
Phase 3 trials typically run 1-4 years. Based on the press release, the trial is set to begin later this year (2026), with results expected in the second half of 2028. After that comes the formal FDA approval process. So realistically, if everything goes well, we might be looking at roughly 3-5 years before this could become available to the public.